Comparison Between Topical Mitomycin C and Cyclosporine

• Status: Completed
• Trial end date: 2022-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Pterygium is a disease associated with proliferation of the fibrovascular tissues of the conjunctiva into the cornea and is related to factors such as ultraviolet light exposure, chronic stimulation, inflammation, climate, and genetics.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Egymedicalpedia
• Treatments: Cyclosporine; Cyclosporins; Mitomycin; Mitomycins

Criteria

Inclusion Criteria:

• Diagnosis of primary pterygium

• Pterygium size > or equal 2mm (the horizontal length of the tissue from limbus to cornea will be measured by slit lamp biomicroscopy).

• Ocular discomfort refractory to medical treatment.

• Visual loss induced by pterygium.

• Adult Egyptian population

Exclusion Criteria:

• Patients who had recurrent pterygium or allergy to topical Cyclosporine.

• Patients who had allergy from Mitomycin C.

• Pregnant women.

• Patients with uncontrollable systemic diseases such as hypertension, diabetes, or cardiovascular diseases.

• Patients with diseases of the eye surface such as conjunctivitis and keratitis.

• Patients with a history of eye surgery within the previous six months.